@joy_chronic @themsguide I’ve double checked, and all the Research Material at my disposal only applies the 55 year age reduction in efficacy to First and Second Line MS DMDs Third Line DMDs are not affected directly by age alone The other factors you stat
@themsguide @joy_chronic All the research that I’ve read categorically only applies to First and Second Line DMDs Nothing about age limit applies to Third Line DMDs like Lemtrada https://t.co/x8h2uf9cdH
Open Access UCL Research: Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population - UCL Discovery https://t.co/akBFE3vEzF
Proud to see our work published: Disease-Modifying Drug Uptake and Health Service Use in the Ageing #MultipleSclerosis Population https://t.co/ywcodbmRSK #NeuroTwitter